Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJun 16, 2026
DataAggregated Company Financials
Companies9
  • 7D1.9%
  • 3M1.1%
  • 1Y27.5%
  • YTD5.3%

The Pharma industry is up 1.9% in the last week, with Novartis up 2.5%. In the last 12 months, the industry was up 27%. As for the next few years, earnings are expected to grow by 11% per annum.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 16 Jun 2026CHF 555.2bCHF 121.9bCHF 24.9b39.8x22.3x4.6x
Thu, 14 May 2026CHF 551.4bCHF 121.0bCHF 24.7b41x22.3x4.6x
Sat, 11 Apr 2026CHF 557.6bCHF 121.6bCHF 25.2b38.9x22.1x4.6x
Mon, 09 Mar 2026CHF 578.5bCHF 120.7bCHF 25.1b35x23.1x4.8x
Wed, 04 Feb 2026CHF 573.6bCHF 119.5bCHF 24.7b39.5x23.3x4.8x
Fri, 02 Jan 2026CHF 560.6bCHF 120.9bCHF 21.5b34.9x26.1x4.6x
Sun, 30 Nov 2025CHF 532.3bCHF 121.6bCHF 21.6b37.1x24.6x4.4x
Tue, 28 Oct 2025CHF 489.7bCHF 120.1bCHF 20.9b33.7x23.4x4.1x
Thu, 25 Sep 2025CHF 471.5bCHF 120.1bCHF 20.9b31.4x22.6x3.9x
Sat, 23 Aug 2025CHF 480.6bCHF 120.5bCHF 21.0b31.1x22.9x4x
Mon, 21 Jul 2025CHF 441.5bCHF 119.2bCHF 19.6b24.8x22.5x3.7x
Wed, 18 Jun 2025CHF 446.4bCHF 118.6bCHF 19.2b25.1x23.3x3.8x
Fri, 16 May 2025CHF 426.9bCHF 119.8bCHF 19.4b24.7x22x3.6x
Sun, 13 Apr 2025CHF 393.9bCHF 117.3bCHF 18.4b23.4x21.4x3.4x
Tue, 11 Mar 2025CHF 489.1bCHF 121.6bCHF 19.1b29.5x25.6x4x
Thu, 06 Feb 2025CHF 468.6bCHF 122.5bCHF 19.1b23x24.5x3.8x
Sat, 04 Jan 2025CHF 429.0bCHF 119.6bCHF 21.4b17.9x20x3.6x
Mon, 02 Dec 2024CHF 435.0bCHF 117.8bCHF 21.1b18.6x20.6x3.7x
Wed, 30 Oct 2024CHF 457.1bCHF 116.9bCHF 20.9b19.9x21.8x3.9x
Fri, 27 Sep 2024CHF 454.7bCHF 114.6bCHF 19.3b21.8x23.6x4x
Sun, 25 Aug 2024CHF 472.1bCHF 114.7bCHF 19.3b22.5x24.5x4.1x
Tue, 23 Jul 2024CHF 457.4bCHF 116.9bCHF 20.6b32.7x22.2x3.9x
Thu, 20 Jun 2024CHF 430.5bCHF 115.5bCHF 19.6b33.9x21.9x3.7x
Sat, 18 May 2024CHF 417.8bCHF 113.3bCHF 19.9b40.3x21x3.7x
Mon, 15 Apr 2024CHF 400.4bCHF 112.6bCHF 19.5b36.7x20.5x3.6x
Wed, 13 Mar 2024CHF 391.9bCHF 110.2bCHF 19.7b23.8x19.9x3.6x
Fri, 09 Feb 2024CHF 376.9bCHF 110.0bCHF 19.6b24x19.2x3.4x
Sun, 07 Jan 2024CHF 412.8bCHF 119.3bCHF 18.6b26.8x22.2x3.5x
Tue, 05 Dec 2023CHF 397.9bCHF 120.7bCHF 18.8b24.9x21.1x3.3x
Thu, 02 Nov 2023CHF 383.5bCHF 123.1bCHF 19.2b23.6x20x3.1x
Sat, 30 Sep 2023CHF 407.6bCHF 113.6bCHF 18.2b44.5x22.4x3.6x
Mon, 28 Aug 2023CHF 405.7bCHF 112.0bCHF 17.9b47.7x22.6x3.6x
Wed, 26 Jul 2023CHF 419.8bCHF 114.2bCHF 19.2b37.8x21.9x3.7x
Fri, 23 Jun 2023CHF 422.1bCHF 115.2bCHF 18.9b37.6x22.4x3.7x
Price to Earnings Ratio

22.4x


Total Market Cap: CHF 422.1bTotal Earnings: CHF 18.9bTotal Revenue: CHF 115.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 9.7% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market2.51%
Healthcare1.45%
Pharma1.91%
Pharma1.91%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVN NovartisCHF 120.222.5%
+CHF 5.3b		24.7%PE20.5x
ROP Roche HoldingCHF 326.101.1%
+CHF 2.7b		24.0%PE20.1x
GALD Galderma GroupCHF 172.953.6%
+CHF 1.4b		56.8%PE83.3x
SDZ Sandoz GroupCHF 67.023.3%
+CHF 926.0m		57.7%PE39.9x
DESN Dottikon ES HoldingCHF 298.002.1%
+CHF 82.9m		3.5%PE39.8x

Latest News

CURN
CHF 24.30
Curatis Holding
7D
9.5%
1Y
103.3%
NOVN
CHF 120.22
Novartis
7D
2.5%
1Y
24.7%
ROP
CHF 326.10
Roche Holding
7D
1.1%
1Y
24.0%
COPN
CHF 71.00
Cosmo
7D
0.3%
1Y
20.7%
SDZ
CHF 67.02
Sandoz Group
7D
3.3%
1Y
57.7%
Narrative Update • Jun 11

SDZ: Elevated Biosimilar Ambitions Will Face Tighter Execution And Margin Scrutiny

Analysts have lifted their CHF price target on Sandoz Group to reflect a fair value shift from about CHF 45.23 to roughly CHF 47.30, citing updated assumptions on revenue growth, margins, and future P/E expectations shaped by recent upgrades, downgrades, and target changes across the Street. Analyst Commentary Recent Street research on Sandoz Group has been mixed, with some firms expressing confidence through upgrades and higher price targets, while others are more cautious.
ADXN
CHF 0.046
Addex Therapeutics
7D
6.0%
1Y
-25.6%
GALD
CHF 172.95
Galderma Group
7D
3.6%
1Y
56.8%
Narrative Update • Jun 03

GALD: Rising Optimism Will Meet Acne Franchise Concentration Risk

Analysts have lifted the Galderma Group price target by about CHF 1 to roughly CHF 183.50, reflecting updated views on fair value, slightly adjusted revenue growth and profit margin assumptions, and continued supportive research commentary across several firms. Analyst Commentary Recent research has focused on how Galderma can execute on its growth plans while justifying higher valuation ranges, with several firms adjusting price targets and ratings in quick succession.
DESN
CHF 298.00
Dottikon ES Holding
7D
2.1%
1Y
3.5%
NWRN
CHF 12.10
Newron Pharmaceuticals
7D
-0.8%
1Y
68.1%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 26.20
BioVersys
7D
-1.5%
1Y
-26.4%